

**Diaceutics PLC**  
**("Diaceutics" or the "Company")**

**Issue of Share Options/PDMR Shareholdings**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of £0.002 each in the Company ("**Share Options**") to certain Directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan.

Share Options were granted as follows:

<b>Name</b>	<b>Number of Share Options granted</b>	<b>Total no. of ordinary shares under option post grant</b>	<b>% of existing issued share capital</b>	<b>Effective Grant date</b>
Peter Keeling, CEO	73,542	253,542	0.30%	1 April 2021
Philip White, CFO	64,154	244,154	0.29%	1 April 2021
Ryan Keeling, CIO	64,154	244,154	0.29%	1 April 2021
Damian Thornton, COO and PDMR	64,062	166,766	0.20%	1 April 2021
Jordan Clark, CCO and PDMR	46,003	122,117	0.15%	1 April 2021
Susanne Munksted, PDMR	45,475	116,147	0.14%	1 April 2021
Other employees (36 persons)	534,581	869,811	1.03%	1 April 2021

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, measured using the average mid-market closing share price in the month immediately before the end of the Performance Period, plus any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 102.67p, being the average mid-market closing share price in the three days prior to 1 April 2021, when the options were issued. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 2,016,687, representing approximately 2.4% of its current issued share capital of 84,063,923.

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer  
Philip White, Chief Financial Officer

[www.diaceutics.com](http://www.diaceutics.com)  
via Walbrook PR

**Centkos Securities plc (Nominated adviser and broker)**

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

+44 (0)207 397 8900

**Walbrook PR**

Anna Dunphy  
Paul McManus

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)  
Mob: +44 (0)7876 741 001  
Mob: +44 (0)7980 541 893

**About Diaceutics**

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - the Diagnostic Network<sup>®</sup> provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform. [www.diaceutics.com](http://www.diaceutics.com)

**About DXRX - The Diagnostic Network<sup>®</sup>**

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>						
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>						
a.	Name	Peter Keeling				
<b>2 Reason for notification</b>						
a.	Position/Status	Chief Executive Officer				
b.	Initial notification/ Amendment	Initial				
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of £0.002 per share</td> <td>73,542</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of £0.002 per share	73,542
Price(s)	Volume(s)					
Exercise price of £0.002 per share	73,542					
e.	Date of the transaction	1 April 2021				
f.	Place of the transaction	Outside a trading venue				

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Philip White
<b>2 Reason for notification</b>		
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of £0.002 per share</td> <td>64,154</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of £0.002 per share	64,154
Price(s)	Volume(s)					
Exercise price of £0.002 per share	64,154					
e.	Date of the transaction	1 April 2021				
f.	Place of the transaction	Outside a trading venue				

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>						
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>						
a.	Name	Ryan Keeling				
<b>2 Reason for notification</b>						
a.	Position/Status	Chief Innovation Officer				
b.	Initial notification/ Amendment	Initial				
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of £0.002 per share</td> <td>64,154</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of £0.002 per share	64,154
Price(s)	Volume(s)					
Exercise price of £0.002 per share	64,154					
e.	Date of the transaction	1 April 2021				
f.	Place of the transaction	Outside a trading venue				

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>						
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>						
a.	Name	Damian Thornton				
<b>2 Reason for notification</b>						
a.	Position/Status	Chief Operating Officer				
b.	Initial notification/ Amendment	Initial				
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of £0.002 per share</td> <td>64,062</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of £0.002 per share	64,062
Price(s)	Volume(s)					
Exercise price of £0.002 per share	64,062					
e.	Date of the transaction	1 April 2021				
f.	Place of the transaction	Outside a trading venue				

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Jordan Clark
<b>2 Reason for notification</b>		
a.	Position/Status	Chief Technology Officer
b.	Initial notification/ Amendment	Initial
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each</b>		

<b>type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of £0.002 per share</td> <td>46,003</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of £0.002 per share	46,003
Price(s)	Volume(s)					
Exercise price of £0.002 per share	46,003					
e.	Date of the transaction	1 April 2021				
f.	Place of the transaction	Outside a trading venue				

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>						
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>						
a.	Name	Susanne Munksted				
<b>2 Reason for notification</b>						
a.	Position/Status	Managing Director and PDMR				
b.	Initial notification/ Amendment	Initial				
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of £0.002 per share</td> <td>45,475</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of £0.002 per share	45,475
Price(s)	Volume(s)					
Exercise price of £0.002 per share	45,475					
e.	Date of the transaction	1 April 2021				
f.	Place of the transaction	Outside a trading venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEBGGDSCGGDGBL